<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The physiological role of thyreoliberin (TRH) is the preservation of homeostasis within four systems (i) the hypothalamic-hypophsysiotropic neuroendocrine system, (ii) the brain stem/midbrain/spinal cord system, (iii) the limbic/cortical system, and (iv) the chronobiological system. Thus TRH, via various cellular mechanisms, regulates a wide range of biological processes (arousal, sleep, learning, locomotive activity, mood) and possesses the potential for unique and widespread applications for treatment of human illnesses. Since the therapeutic potential of TRH is limited by its pharmacological profile (enzymatic instability, short half-life, undesirable effects), several synthetic analogues of TRH were constructed and studied in mono- or adjunct therapy of central nervous system (CNS) disturbances. The present article summarizes the current state of understanding of the physiological role of TRH and describes its putative role in clinical indications in CNS maladies with a focus on the action of TRH analogues.</p></abstract>

Tyreoliberin (Trh) – The Regulatory Neuropeptide of Cns Homeostasis

<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The life span of adult cells is restricted, becoming senescent and eventually undergoing apoptosis. Cells are replaced by new ones which originate from a population of stem cells. An example is provided by the hemopoietic system in the bone marrow. In an adult body, stem cells may be identified by markers present in both embryonic and tissue-specific stem cells. Oct3/4, CXCR4, Nanog, CD133 and CD34 are examples of such markers. The stem cells share several properties, such as they may: 1) replicate and give rise to new stem cells, 2) differentiate into heterogenous tissue and organ specific cells and, finally, 3) stem cells are self-protected against various toxic agents and radiation. In adult tissues, stem cells reside in specialized sites (niches), for example in the bone marrow, skin, digestive tract epithelium, and skeletal muscles. Stem cells residing in these stem cell niches are anchored there by chemokines and adhesion molecules. Stroma-Derived Factor-1 (SDF-1), α-chemokine and stem-cell expressed receptor CXCR4 play an important role in the retention of stem cells in such niches. Several stress factors may attenuate the SDF-1-CXCR4 axis in the bone marrow, which leads to the release of stem cells from their niches into circulation. Another important stem cell niche-anchoring mechanism is the interaction of Wnt (a ligand) with Frizzled LRP (receptor). The recently accumulated evidence suggests that malignancy arises from an arrest in maturation and mutation of stem cells. Cancer stem cells are responsible for tumor growth, its relapse and metastasis<bold>. </bold>The first direct evidence for the existence of cancer stem cells came from observations of acute myeloblastic leukemia. Currently, cell populations enriched for cancer stem cells have been isolated from several tumors. The cancer stem cells represent less than 1% of tumor cells in the mouse models.</p></abstract>

Stem Cells of Adult Organisms in Biology and Medicine

AHEAD OF PRINT

Volume 11 (2023): Issue 4 (December 2023)

Volume 11 (2023): Issue 3 (December 2023)

Volume 11 (2023): Issue 2 (September 2023)

Volume 11 (2023): Issue 1 (July 2023)

Volume 10 (2022): Issue 4 (December 2022)

Volume 10 (2022): Issue 3 (September 2022)

Volume 10 (2022): Issue 2 (June 2022)

Volume 10 (2022): Issue 1 (March 2022)

Volume 9 (2021): Issue 4 (December 2021)

Volume 9 (2021): Issue 3 (September 2021)

Volume 9 (2021): Issue 2 (June 2021)

Volume 9 (2021): Issue 1 (March 2021)

Volume 8 (2020): Issue 4 (December 2020)

Volume 8 (2020): Issue 3 (December 2020)

Volume 8 (2020): Issue 2 (June 2020)

Volume 8 (2020): Issue 1 (March 2020)

Volume 7 (2019): Issue 4 (December 2019)

Volume 7 (2019): Issue 3 (October 2019)

Volume 7 (2019): Issue 2 (September 2019)

Volume 7 (2019): Issue 1 (July 2019)

Volume 6 (2018): Issue 4 (December 2018)

Volume 6 (2018): Issue 3 (December 2018)

Volume 6 (2018): Issue 2 (September 2018)

Volume 6 (2018): Issue 1 (January 2018)

Volume 5 (2017): Issue 2 (September 2017)

Volume 5 (2017): Issue 1 (March 2017)

Volume 4 (2014): Issue 2 (December 2014)

Volume 4 (2014): Issue 1 (March 2014)

Volume 3 (2011): Issue 4 (November 2011)

Volume 3 (2011): Issue 3 (October 2011)

Volume 3 (2011): Issue 2 (June 2011)

Volume 3 (2011): Issue 1 (February 2011)

Volume 2 (2010): Issue 4 (November 2010)

Volume 2 (2010): Issue 3 (April 2010)

Volume 2 (2010): Issue 2 (February 2010)

Volume 2 (2010): Issue 1 (January 2010)

Medical Journal of Cell Biology

 Information for Polish Scientists   Zgodnie z Komunikatem Ministra Nauki i Szkolnictwa Wyższego z dnia 31 lipca 2019 r. czasopismo Medical Journal of Cell Biology uzyskało 20 punktów MNiSW.  Zachęcamy Państwa do nadsyłania artykułów zgodnych z profilem tematycznym czasopisma.     The Medical Journal of Cell Biology (MJCB) is published by Sciendo owned by De Gruyter and held by the Foundation for Cell Biology and Molecular Biology. The MJCB publishes articles in open access system in English only, four times per year, predominantly in but not limited to the field of cell biology, cell and tissue engineering, as well as translational medical studies. The journal accepts both original works, which are an innovative contribution to the field of science and critical reviews relevant to the latest literature, not older than five years. Periodically, Editor in Chief, with the permission of the Managing Editor, accepts selected Clinical Case Reports.  AIMS  Medical Journal of Cell Biology (ISSN 2544-3577) is an international, double-blind peer-reviewed, open access journal. Our predominant aim is to provide an accessible but specialized platform for researches in the field of cell biology, cell and tissue engineering, as well as translational medical studies. Manuscripts related to regenerative and reconstructive medicine are especially anticipated. Each presented methodology must be precisely described to enable reproducibility of the results. However there is no limit for the length of the manuscripts, as well as for the number of included figures and tables. MJCB provides efficient review process, followed by prompt publication of latest scientific discoveries to enrich the knowledge of researchersacross the globe.   The MJCB accepts the following types of publications: research articles, review articles, clinical case reports, letters, editorials and short communications.   SCOPE  The Medical Journal of Cell Biology accepts publications covering the following thematic areas:     Biology of human, animal and plant cells  Biology of stem cells  Biology of microbes  Biotechnology and bioengineering of cells and tissues  Nanotechnology  Reconstructive and regenerative medicine  Molecular biology  Carcinogenesis and pharmacotherapy     Why subscribe and read   Comparison of plant and animal cell biology   Rejection Rate   40%   Archiving  Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.  Plagiarism Policy  The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 

Medical Journal of Cell Biology

Volume 2 (2010): Issue 4 (November 2010)

Tyreoliberin (Trh) – The Regulatory Neuropeptide of Cns Homeostasis

Stem Cells of Adult Organisms in Biology and Medicine

Suche

Alle Bände und Hefte dieser Zeitschrift